Related Parties

12 Months Ended

Dec. 31, 2023

Related Party Transactions [Abstract]

Related Parties

18. Related Parties

The Company was founded out of Dr. Thomas Gajewski’s laboratory at the University of Chicago. In 2020, the Company entered into the License Agreement with the University of Chicago, as well as a sponsored research agreement. The Company incurred expenses of $0.2 million and $0.3 million during the years ended December 31, 2023 and 2022, respectively, with regards to the University License Agreement. Refer to Note 4, Licensing Agreements, for additional discussion.

Pfizer owns more than 10% of the Company and is considered the principal owner of the Company. The Company incurred expenses of $0 and $17.3 million during the years ended December 31, 2023 and 2022, respectively, with regards to the Pfizer A&R License Agreement. Refer to Note 4, Licensing Agreements, for additional discussion.

The Company and Alloy formed a joint venture company, Voxall Therapeutics, LLC (“Voxall”) to leverage the Company’s technology and Alloy’s ATX-Gx™ platform and antibody discovery services. The Company and Alloy contributed $50 thousand each to Voxall along with certain license in 2021. The Company did not incur expenses during the years ended December 31, 2023 and 2022 with regards to Voxall. Refer to Note 5, Joint Venture, and Note 20, Subsequent Events, for additional discussion.